Agios Bolsters Coffers With $1.1 Bln Milestone Payments Following FDA Approval Of Vorasidenib

Agios Pharmaceuticals Inc. (AGIO) is all set to strengthen its cash reserves with over a billion dollars in milestone payments. The news was well received by investors, sending the stock up over 10% to $46 in after-hours trading.

What triggered a billion-dollar windfall?

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com